CompletedNot Applicable

An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms

United States20 participantsStarted 2004-09

Plain-language summary

The purpose of this study is to see if galantamine is an effective agent for the treatment of the cognitive abnormalities, negative symptoms, and /or behavioral impairments seen in schizophrenia.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Fulfills DSM-IV criteria for schizophrenia. * Unable to achieve competitive employment status within the past five years. * Unable to live independently in the community. * Maintained on a stable regimen of antipsychotic medication for at least two weeks prior to enrollment. Exclusion Criteria: * History of significant hepatic, renal, pulmonary, endocrine, active peptic ulcer disease or cardiovascular disease. * History of seizure disorder and/or head injury. * Co-morbid substance use/abuse disorder. * Received an investigational medication within the previous month. * Due to the risk of adverse effects on fetal development: women with any risk of becoming pregnant will be excluded from this study.

What they're measuring

This trial is an exploratory open-label trial; thus, several outcome measures are employed in order to detect possible therapeutic effects in the negative symptom domain of psychopathology

Trial details

NCT IDNCT00161044

SponsorUniversity of Maryland, Baltimore

Sponsor typeOTHER

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Chronic Schizophrenia trials